HIV, metabolic syndrome X, inflammation, oxidative stress, and coronary heart disease risk: Role of protease inhibitor exposure

Cardiovascular Toxicology

Volumn 4, Issue 3, 2004, Pages 303-315

  Hurwitz, Barry E ^a,b,d   Klimas, Nancy G ^a,c   Llabre, Maria M ^a,b   Maher, Kevin J ^a,c   Skyler, Jay S ^a   Bilsker, Martin S ^a,c   McPherson Baker, Shvawn ^a,c   Lawrence, Peter J ^a   LaPerriere, Arthur R ^a,c   Greeson, Jeffrey M ^b   Klaus, Johanna R ^b   Lawrence, Rasha ^a   Schneiderman, Neil ^a,b,c  

^a UNIVERSITY OF MIAMI   (United States)

^b Department of Biology   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Coronary heart disease risk; HAART; HIV AIDS; Inflammation; Metabolic syndrome X; Oxidative stress

Indexed keywords

ANTIRETROVIRUS AGENT; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISOPROSTANE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEINASE INHIBITOR; TRIACYLGLYCEROL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DYSLIPIDEMIA; ENZYME INHIBITION; ETHNIC DIFFERENCE; EXPOSURE; FEMALE; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INFLAMMATION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK ASSESSMENT; SEROCONVERSION; SEX DIFFERENCE; T LYMPHOCYTE ACTIVATION;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHOLESTEROL; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HIV PROTEASE INHIBITORS; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HUMANS; INFLAMMATION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OXIDATIVE STRESS; RISK; RISK ASSESSMENT; TRIGLYCERIDES;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 20844453563     PISSN: 15307905     EISSN: None     Source Type: Journal    
DOI: 10.1385/CT:4:3:303     Document Type: Article

References (70)

1. Vigoureux, C., Gharakhanian, S., Salhi, Y., Nguyen, T.H., Adda, N., Rozenbaum, W., et al. (1999). Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease. Diabetes Metab. 25:383-392.
2. John, M., Nolan, D., and Mallal, S. (2001). Antiretroviral therapy and the lipodystrophy syndrome. Antivir. Ther. 6:9-20.
3. Nolan, D. and Mallal, S. (2001). Getting to the HAART of insulin resistance. AIDS 15:2037-2041.
4. Reaven, G.M. (1995). Pathophysiology of insulin resistance in human disease. Physiol. Rev. 75:473-486.
5. Schneiderman, N. and Skyler, J.S. (1996). Insulin metabolism, sympathetic nervous system regulation, and coronary heart disease prevention, in Behavioral Medicine Approaches to Cardiovascular Disease Prevention (Orth-Gomer, K. and Schneiderman, N., eds.), Lawrence Erlbaum Associates, Mahwah, NJ, pp. 105-133.
6. Dube, M.P., Sprecher, D., Henry, W.K., Aberg, J.A., Torriani, F.J., Hodis, H.N., et al. (2000). Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clin. Infect. Dis. 31:1216-1224.
7. Hadigan, C., Meigs, J.B., Corcoran, C., Rietschel, P., Piecuch, S., Basgoz, N., et al. (2001). Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin. Infect. Dis. 32:130-139.
8. Mynarcik, D.C., McNurlan, M.A., Steigbigel, R.T., Fuhrer, J., and Gelato, M.C. (2000). Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J. Acquir. Immune Defic. Syndr. 25:312-321.
9. Ross, R. (1999). Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340:115-126.
10. Dinarello, C.A. (1989). Interleukin-1 and its biologically related cytokines. Adv. Immunol. 44:153-205.
11. Aldhahi, W. and Hamdy, O. (2003). Adipokines, inflammation, and the endothelium in diabetes. Curr. Diab. Rep. 3:293-298.
12. Birks, E.J. and Yacoub, M.H. (1997). The role of nitric oxide and cytokines in heart failure. Coron. Artery Dis. 8:389-402.
13. Witztum, J.L. (1994). The oxidation hypothesis of atherosclerosis. Lancet 344:793-798.
14. Barbaro, G. (2001). Cardiovascular manifestations of HIV infection. J. R. Soc. Med. 94:384-390.
15. Libby, P. and Ridker, P.M. (1999). Novel inflammatory markers of coronary risk: theory versus practice. Circulation 100:1148-1150.
16. Lagrand, W.K., Visser, C.A., Hermens, W.T., Niessen, H.W., Verheugt, F.W., Wolbink, G.J., et al. (1999). C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation 100:96-102.
17. Ridker, P.M., Hennekens, C.H., Buring, J.E., and Rifai, N. (2000). C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342:836-843.
18. Sklar, P. and Masur, H. (2003). HIV infection and cardiovascular disease - is there really a link? N. Engl. J. Med. 349:2065-2067.
19. Mason, A.L., Lau, J.Y., Hoang, N., Qian, K., Alexander, G.J., Xu, L., et al. (1999). Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 29:328-333.
20. Ockenga, J., Tillmann, H.L., Trautwein, C., Stoll, M., Manns, M.P., and Schmidt, R.E. (1997). Hepatitis B and C in HIV-infected patients: prevalence and prognostic value. J. Hepatol. 27:18-24.
21. Centers for Disease Control, CDC. (1993). 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA 6:729-730.
22. The Florida Division of Disease Control Quarterly Surveillance Report: Bureau of HIV/AIDS. March 2002, Number 211. http://www.doh.state.fl.us/ disease_ctrl/aids/trends/ msr/msr.html
23. Brownley, K.A., Milanovich, J.R., Motivala, S.J., Schneiderman, N., Pillion, L., Graves, J. A., et al. (2001). Autonomic and cardiovascular function in HIV spectrum disease: early indications of cardiac pathophysiology. Clin. Auton. Res. 11:319-326.
24. DeFronzo, R.A., Tobin, J.D., and Andres, R. (1979). The glucose clamp technique: a method for quantifying insulin secretion and resistance. Am. J. Physiol. 6:E214-E223.
25. Allain, C.C., Poon, L.S., Chan, C.S., Richmond, W., and Fu, P.C. (1974). Enzymatic determination of total serum cholesterol. Clin. Chem. 20:470-475.
26. McGowan, M.W., Artiss, J.D., Strandbergh, D.R., and Zak, B. (1983). A peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clin. Chem. 29:538-542.
27. 2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin. Chem. 28:1379-1388.
28. Friedewald, W.T., Levy, R.S., and Fredrickson, D.S. (1972). Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin. Chem. 18:449-502.
29. Motivala, S.J., Hurwitz, B.E., Llabre, M.M., Klimas, N.G., Fletcher, M.A., Antoni, M.H., et al. (2003). Psychological distress is associated with decreased memory T-helper and B-cell counts in pre-AIDS HIV seropositive men and women but only in those with low viral load. Psychosom. Med. 65:627-635.
30. Koning, A.J. and Silk, M.H. (1963). The 2-thiobarbituric acid reagent for determination of oxidative rancidity in fish oils. J. Am. Oil Chem. Soc. 40:165-169.
31. Reilly, M.P., Delanty, N., Roy, L., Rokach, J., Callaghan, P.O., Crean, P., et al. (1997). Increased formation of the isoprostanes IPF2alpha-1 and 8-epi-prostaglandin F2 alpha in acute coronary angioplasty: evidence for oxidant stress during coronary reperfusion in humans. Circulation 96:3314-3320.
32. Pratico, D., Iuliano, L., Mauriello, A., Spagnoli, L., Lawson, J.A., Rokach, J., et al. (1997). Localization of distinct F2-isoprostanes in human atherosclerotic lesions. J. Clin. Inves. 100:2028-2034.
33. Gopaul, N.K., Anggard, E.E., Mallet, A.I., Betteridge, D.J., Wolff, S.P., and Nourooz-Zadeh, J. (1995). Plasma 8-epi-PGF2 alpha levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Lett. 368:225-229.
34. Moore, K. and Roberts, L.J. (1998). Measurement of lipid peroxidation. Free Radic. Res. 28:659-671.
35. Wilson, P.W., D'Agostino, R.B., Levy, D., Belanger, A.M., Silbershatz, H., and Kannel, W.B. (1998). Prediction of coronary heart disease using risk factor categories. Circulation 97:1837-1847.
36. Assmann, G., Cullen, P., and Schulte, H. (2002). Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 105:310-315.
37. National Cholesterol Education Program (Adult Treatment Panel III). (2001). JAMA 285:2486-2495.
38. Haq, I.U., Ramsay, L.E., Jackson, P.R., and Wallis, E.J. (1999). Prediction of coronary risk for primary prevention of coronary heart disease: a comparison of methods. QJM 92:379-385.
39. Grundy, S.M., Pasternak, R., Greenland, P., Smith, S. Jr., and Fuster, V. (1999). AHA/ACC scientific statement: assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J. Am. Coll. Cardiol. 34:1348-1359.
40. Hense, H.W., Schulte, H., Lowel, H., Assmann, G., and Keil, U. (2003). Framingham risk function overestimates risk of coronary heart disease in men and women from Germany - results from the MONICA Augsburg and the PROCAM cohorts. Eur. Heart J. 24:937-945.
41. Vittecoq, D., Escaut, L., Merad, M., Teicher, E., Monsuez, J.J., and Chironi. G. (2003). Coronary heart disease in HIV-infected individuals, in Advances in Cardiology: HIV Infection and the Cardiovascular System (Barbaro, G., ed.), Karger, New York, pp. 151-162.
42. Goldstein, R.Z., Hurwitz, B.E., Llabre, M.M., Schneiderman, N., Gutt, M., Skyler, J.S., et al. (2001). Modeling preclinical cardiovascular risk for use in epidemiological studies: the Miami Community Health Study. Am. J. Epidemiol. 154:765-776.
43. Haffner, S.M., Fong, D., Hazuda, H.P., Pugh, J.A., and Patterson, J.K. (1988). Hyperinsulinemia, upper body adiposity, and cardiovascular risk factors in non-diabetics. Metabolism 37:338-345.
44. Shen, B.J., Todaro, J.F., Niaura, R., McCaffery, J.M., Zhang, J., Spiro, A. III, et al. (2003). Are metabolic risk factors one unified syndrome? Modeling the structure of the metabolic syndrome X. Am. J. Epidemiol. 157:701-711.
45. Niaura, R., Todaro, J.F., Stroud, L., Spiro, A. III, Ward, K.D., and Weiss, S. (2002). Hostility, the metabolic syndrome, and incident coronary heart disease. Health Psychol. 21:588-593.
46. Carr, A., Samaras, K., Burton, S., Law, M., Freund, J., Chisholm, D.J., et al. (1998). A syndrome of peripheral lipodystrophy hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12:F37-F39.
47. Dube, M.P., Johnson, D.L., Currier, J.S., and Leedom, J.M. (1997). Protease inhibitor-associated hyperglycemia. Lancet 350:713-714.
48. Meyer, L., Rabaud, C., Ziegler, O., May, T., and Drouin, P. (1998). Protease inhibitors, diabetes mellitus and blood lipids. Diabetes Metab. 24:547-549.
49. Walli, R., Herfort, O., Michl, G.M., Demant, T., Jager, H., Dieterle, C., et al. (1998). Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1 infected patients. AIDS 12:F167-F173.
50. Martinez, E. and Gatell, J.M. (1999). Metabolic abnormalities and body fat redistribution in HIV-1 infected patients: the lipodystrophy syndrome. Curr. Opin. Infect. Dis. 12:13-19.
51. Geffner, M.E., Yen, D.Y., Landaw, E.M., Scott, M.L., Stiehm, E.R., Bryson, Y.J., et al. (1993). In vitro insulin-like growth factor-1, growth hormone, and insulin resistance occurs in symptomatic human immunodeficiency virus-1-infected children. Pediatr. Res. 34:66-72.
52. Hellerstein, M.K., Grunfeld, C., Wu, K., Christiansen, M., Kaempfer, S., Kletke, C., et al. (1993). Increased de novo hepatic lipogenesis in human immunodeficiency virus infection. J. Clin. Endocrinol. Metab. 73:559-565.
53. Grunwald, C., Kotler, D.P. Hamadeh, R., Tierney, A., Wang, J., and Pierson R.N. (1989). Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am. J. Med. 86:27-31.
54. Constans, J., Pellegrin, J.L., Peuchant, E., Dumon, M.F., Pellegrin, L, Sergeant, C., et al. (1994). Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur. J. Clin. Invest. 24:416-420.
55. Duong, M., Petit, J.M., Piroth, L., Grappin, M., Buisson, M., Chavanet, P., et al. (2001). Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 27:245-250.
56. Huffman, C. and Jaeger, H. (2001). Cardiology and AIDS-HAART and the consequences. Ann. NY Acad. Sci. 946:130-144.
57. Cullen, P. (2000). Evidence that triglycerides are an independent coronary heart disease risk factor. Am. J. Cardiol. 86:943-949.
58. Assmann, G. (2001). Pro and con: high-density lipoprotein, triglycerides, and other lipid subfractions are the future of lipid management. Am. J. Cardiol. 87(Suppl.):2B-7B.
59. Carr, A., Samaras, K., Chisholm, D.J., and Cooper, D.A. (1998). Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 351:1881-1883.
60. Behrens, G.M.N., Stoll, M., and Schmidt, R.E. (2003). Pathogenesis of the HAART-associated metabolic syndrome, in Advances in Cardiology: HIV Infection and the Cardiovascular System (Barbara, G., ed.), Karger, New York, pp. 83-96.
61. Wilkinson, J. and Gotch, F. (2001). Immune interventions. Br. Med. Bull. 58:187-203.
62. Gandhi, R.T. and Walker, B.D. (2002). Immunologic control of HIV-1. Annu. Rev. Med. 53:149-172.
63. Yamamoto, N. (1994). The role of cytokines in the acquired immunodeficiency syndrome. Int. J. Clin. Lab. Res. 25:29-34.
64. Heine, R.J. and Dekker, J.M. (2002). Beyond postprandial hyperglycaemia: metabolic factors associated with cardiovascular disease. Diabetologia 45:461-475.
65. Hajjar, D.P. and Haberland, M.E. (1997). Lipoprotein trafficking in vascular cells. Molecular Trojan horses and cellular saboteurs. J. Biol. Chem. 272:22975-22978.
66. Hansson, G.K., Jonasson, L., Seifert, P.S., and Stemme, S. (1989). Immune mechanisms in atherosclerosis. Arteriosclerosis 9:567-578.
67. Pelchen-Matthews, A., Signoret, N., Klasse, P.J., Fraile-Ramos, A., and Marsh, M. (1999). Chemokine receptor trafficking and viral replication. Immunol. Rev. 168:33-49.
68. Peterhans, E. (1997). Reactive oxygen species and nitric oxide in viral diseases. Biol. Trace Elem. Res. 56:107-116.
69. Piette, J. and Legrand-Poels, S. (1994). HIV-1 reactivation after an oxidative stress mediated by different reactive oxygen species. Chem. Biol. Interact. 91:79-89.
70. Schreck, R., Rieber, P., and Baeuerle, P.A. (1991). Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J. 10:2247-2258.